From: Fauci, Anthony (NIH/NIAID) [E]

Sent: Mon, 23 Mar 2020 14:48:07 +0000

To:

Cc: Conrad, Patricia (NIH/NIAID) [E]

Subject: FW: 23-3-2020 FAO Dr Birx and Dr Fauci - Covid-19 Task Force RE:- Favipiravir =
Avigan

Please have someone handle.

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03

31 Center Drive, MSC 2520

National Institutes of Health

Bethesda, MD a0 e 20n0

 

The information in this =-mail and any of its attachments is confidential and may contain sensitive
information. It should not be used by anyone who is not the original intended recipient. If you
have received this e-mail in error please inform the sender and delete it from your mailbox or any
other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not
accept liability for any statements made that are the sender's own and not expressly made on
behalf of the NIAID by one of its representatives.

From:

Sent: Monday, March 23, 2020 8:32 AM

To: ) Fauci, Anthony (NIH/NIAID) C—O
Ce: NST Rogers
Subject: 23-3-2020 FAO Dr Birx and Dr Fauci - Covid-19 Task on RE:- Favipiravir = Avigan
Importance: High

 

23-3-2020
Dear Dr Birx and Dr Fauci,
As promised, sorry about the delay.

Please see below two articles relating to Favipiravir which has the brand name Avigan. This
appears to have some beneficial effects with regard to the treatment of Covid-19.

| have also included the Wikipedia for Favpiravir.

Good Luck with regard to managing the epidemic/pandemic.

NIH-000292
